Heron Therapeutics Inc
HRTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$74.34M
Close$
$3.67
705.1% upside
Current Fair Value
705.1% upsideUndervalued by 705.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $74.34 Million |
|---|---|
| Enterprise Value | $189.86 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.12 |
| Beta | 1.65 |
| Outstanding Shares | 189,646,000 |
Return
| Return on Equity | -338.63% |
|---|---|
| Return on Assets | -12.57% |
| Return on Invested Capital | -8.39% |
Valuation & Multiples
| P/E Ratio | -2.66 |
|---|---|
| PEG | 0.65 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 1.26 |
| Enterprise Value to EBIT | -14.54 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.75 |
| Debt to Equity | 15.5 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 11, 2026
EPS Estimate
$-0.03
Average shareholder expectationRevenue Estimate
$36.72 M
Average shareholder expectationNext Earnings Call
Expected Date
August 11, 2026
EPS Estimate
$-0.02
Average shareholder expectationRevenue Estimate
$42.19 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 189.88% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.37%▼ 92.72% |
|---|---|
| Total Invested | $1.40M▼ 98.89% |
| Investors Holding | 15▼ 158.00% |
ESG Score
No data
About Heron Therapeutics Inc
CEO: Barry Quart